sellWeak cluster of 410b5-1 plan
Crispina Calsada sold $55k of RGLS
Chief Financial Officer at Regulus Therapeutics Inc.. 43,804 shares at an average of $1.26, traded Jan 13, 2025, filed Jan 15, 2025.
Warning score
34Value
$55k
43,804 shares
Holdings after
45,478
-49% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +7Trade size$55k at market
- +10Share of holdings soldSold 49% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-005881, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 13, 2025 | SOpen-market sale Common Stock10b5-1 | -38,716 | $1.26 | $49k | 50,566 | Jan 15, 2025 |
| Jan 14, 2025 | SOpen-market sale Common Stock10b5-1 | -5,088 | $1.26 | $6,427 | 45,478 | Jan 15, 2025 |
Related signals
Other insiders at Regulus Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | RGLSbuy Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $96k 12,000 shares | +33% | |
| 33Weak | Regulus Therapeutics Inc. | David Baltimore director | $21k 19,610 shares | +766% | |
| 46Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $54k 50,000 shares | +24% | |
| 27Weak | Regulus Therapeutics Inc. | Christopher Ray Aker Sr. VP & General Counsel | $55k 43,635 shares | -47% | |
| 41Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $160k 127,054 shares | -38% | |
| 31Weak | Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $40k 31,445 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.